The ETA antagonist CI-1020 inhibits hypoxic pulmonary vasoconstriction in small isolated rat pulmonary arteries

被引:6
作者
Jones, RD [1 ]
Morice, AH [1 ]
机构
[1] Univ Hull, Castle Hill Hosp, Acad Dept Med, Sect Resp Med, Cottingham, E Yorkshire, England
关键词
hypoxic pulmonary vasoconstriction; isolated rat pulmonary arteries; CI-1020; endothelin-A receptor;
D O I
10.1006/pupt.1998.0134
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hypoxic pulmonary vasoconstriction (HPV) of rat pulmonary arteries in vitro occurs in four phases, Initial vasodilation (phase 1), is followed by transient contraction (phase 2), further vasodilation (phase 3) and finally a second sustained contraction (phase 4), We have investigated the role of ET-1 in HPV using the ETA receptor antagonist CI-1020, Small rat pulmonary arteries (SPA, n=32, diameter=454+/-22 pill) were mounted in a wire myograph, Two contractions to 80 mu M KCl ensured response reproducibility and relaxation to 10 mu M acetyl choline following constriction with 100 mu M prostaglandin F-2 alpha (PGF(2 alpha)) to indicate endothelial integrity. A control hypoxic response was produced following priming with 5 mu M PGF(2 alpha). Vessels (n = 8) were then exposed to either vehicle or CI-1020 (1, 10 or 100 mu M) for 30 min in the dark before re-exposure to PGF(2 alpha) and hypoxia, Responses were standardized as a percentage of contraction to 80 mM KCI, Vehicle caused an increase in phase 2 of HPV of +2.51+/-4.20% (expressed as difference between pre- and post-drug values). CI-1020 (1, 10 and 100 mu M) caused a significant reduction in phase 2 of HPV of -9.76+/-1.40%, -9.23+/-2.30% and -7.96+/-1.70%, respectively (P<0.05). These results suggest that phase 2 of HPV in rat SPA is attributed, in part, to the action of ET-1 at the ETA receptor. (C) 1998 Academic Press.
引用
收藏
页码:177 / 181
页数:5
相关论文
共 32 条
[1]   Functional comparison of endothelin receptors in human and rat pulmonary artery smooth muscle [J].
Bialecki, RA ;
Fisher, CS ;
Murdoch, WW ;
Barthlow, HG ;
Bertelsen, DL .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1997, 272 (02) :L211-L218
[2]   BQ123, AN ET(A)-RECEPTOR ANTAGONIST, ATTENUATES HYPOXIC PULMONARY-HYPERTENSION IN RATS [J].
BONVALLET, ST ;
ZAMORA, MR ;
HASUNUMA, K ;
SATO, K ;
HANASATO, N ;
ANDERSON, D ;
SATO, K ;
STELZNER, TJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (04) :H1327-H1331
[3]   The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats [J].
Chen, SJ ;
Chen, YF ;
Opgenorth, TJ ;
Wessale, JL ;
Meng, QC ;
Durand, J ;
DiCarlo, VS ;
Oparil, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (06) :713-725
[4]   Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats [J].
Chen, SJ ;
Chen, YF ;
Meng, QC ;
Durand, J ;
Dicarlo, VS ;
Oparil, S .
JOURNAL OF APPLIED PHYSIOLOGY, 1995, 79 (06) :2122-2131
[5]  
CHEN SJ, 1993, FASEB J, V7, pA649
[6]   ET(A)-RECEPTOR ANTAGONIST PREVENTS AND REVERSES CHRONIC HYPOXIA-INDUCED PULMONARY-HYPERTENSION IN RAT [J].
DICARLO, VS ;
CHEN, SJ ;
MENG, QC ;
DURAND, J ;
YANO, M ;
CHEN, YF ;
OPARIL, S .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1995, 269 (05) :L690-L697
[7]   ENDOTHELIN-1 DOES NOT MEDIATE HYPOXIC VASOCONSTRICTION IN CANINE ISOLATED BLOOD-VESSELS - EFFECT OF BQ-123 [J].
DOUGLAS, SA ;
VICKERYCLARK, LM ;
OHLSTEIN, EH .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (02) :418-421
[8]   EXPRESSION OF ENDOTHELIN-1 IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION [J].
GIAID, A ;
YANAGISAWA, M ;
LANGLEBEN, D ;
MICHEL, RP ;
LEVY, R ;
SHENNIB, H ;
KIMURA, S ;
MASAKI, T ;
DUGUID, WP ;
STEWART, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (24) :1732-1739
[9]  
GOERRE S, 1995, CIRCULATION, V91, P359
[10]   ACUTE ALVEOLAR HYPOXIA INCREASES ENDOTHELIN-1 RELEASE BUT DECREASES RELEASE OF CALCITONIN-GENE-RELATED PEPTIDE IN ISOLATED-PERFUSED RAT LUNGS [J].
HELSET, E ;
KJAEVE, J ;
BJERTNAES, L ;
LUNDBERG, JM .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 (05) :369-376